Butterfly - Clinical Performance Study

Thermo Fisher Scientific, Inc1,076 enrolled

Overview

This prospective clinical performance study is a non-interventional, multi-center study to evaluate the assay performance of the COVID-19 test using upper respiratory specimens. Prospectively collected nasopharyngeal and anterior nasal swabs will be collected from each participant recruited in the study.

The Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit (referred to as "COVID-19 test") aims to develop a reverse transcription, real-time polymerase chain reaction (RT-qPCR) test for the qualitative detection of SARS-CoV-2. The purpose of this study is to evaluate the clinical performance of the TaqPath™ COVID-19 Diagnostic PCR Kit (COVID-19 test) in nasopharyngeal swabs and anterior nasal swabs from symptomatic individuals suspected of COVID-19 by their health care provider. A composite comparator approach will be used to evaluate the performance of the COVID-19 test which includes the use of three highly sensitive SARS-CoV-2 molecular assays as comparators. Clinical calls will be compared between COVID-19 test and the three composite comparators. The third comparator assay will only be used to test samples that show discrepant clinical calls between the first two comparator methods, for a two-out-of-three result interpretation. The Clinical Performance Study Protocol (CPS Protocol) outlines the clinical sample collection and testing protocols which will be used to satisfy the FDA 510(k) study requirements in the US.

Study Type

OBSERVATIONAL

Enrollment

1,076

Conditions

COVID-19 Coronavirus Infections

Interventions

Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR KitDIAGNOSTIC_TEST

A reverse transcription, real-time polymerase chain reaction (RT-qPCR) test for the qualitative detection of SARS-CoV-2.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: Participants of all ages must meet the following inclusion criteria to be eligible for participation in the study: * Ability to provide informed consent or assent (as age-appropriate). Stated willingness and ability to comply with the study procedures including nasopharyngeal and anterior nasal swab collection. * Individuals with at least one of the following COVID-19 symptoms: 1. fever or chills 2. congestion or runny nose 3. headache or fatigue 4. muscle or body aches b. new loss of taste or smell c. a new or worsening cough or sore throat d. shortness of breath or difficulty breathing e. decrease in appetite, nausea, vomiting, diarrhea. * Subjects suspected of having COVID-19 symptoms for seven (7) or fewer days. Exclusion Criteria: Participants meeting the following criterion will be excluded from the study: * Subjects suspected of having COVID-19 symptoms for greater than seven (7) days. * Subjects who have provided upper respiratory tract samples for other clinical studies within twenty-four (24) hours

Locations (11)

KUR Research at Exer Urgent Care - Manhattan Beach

Manhattan Beach, California, United States

KUR Research at Exer Urgent Care - Redondo Beach

Redondo Beach, California, United States

Medical Center for Clinical Research

San Diego, California, United States

Outcomes

Primary Outcomes

Clinical performance evaluation of the COVID-19 test

Clinical performance evaluation of the COVID-19 test using a composite comparator approach with upper respiratory specimens to meet PPA and NPA requirements.

Time frame: Between April 2023 and August 2023

Identification of adverse events

Identify any adverse events or complications associated with the COVID-19 test

Time frame: Between April 2023 and August 2023

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.